Welcome to the 3rd JAK Inhibitors Drug Development Summit: Optimize Safety & Selectivity of Your JAK Inhibitor
Following two successful virtual experiences, the 3rd JAK Inhibitors Drug Development Summit is making its way to Boston, MA warmly welcoming the JAK inhibitor community back to in-person meetings.
We are uniting this diverse community of world-leading experts from a range of therapeutic backgrounds all tied together by one thing, treating dermatologic, autoimmune, oncologic and many more inflammatory indications through JAK inhibition.
This remains the only end-to-end industry meeting committed to delivering new JAK inhibitor therapeutics to market through collaboration. This year’s summit bestows an unrivaled prospect to industry experts; debating JAKi safety with benefit-risk conversations, exploring JAK selectivity to elevate precise approaches, reviewing opportunities to foray into indications of unmet need, and embracing discussion around topical/oral/alternate drug delivery methods to accelerate production of the next generation of JAK inhibitors.
With experienced insights into innovative therapeutic methods and answers to current setbacks, the 3rd JAK Inhibitors Drug Development Summit will gather leading pharma, biotech, pioneering academics, and industry stakeholders to optimize safety, selectivity, and efficacy to successfully develop the next generation of JAK inhibitors for dermatology, autoimmunity, and beyond.
As the only industry-led conference dedicated to the unity industry, clinicians, and academia exploring JAK utilization, expect to hear bubbling cross-disciplinary discussions covering a vast expanse of common challenges.